GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Debt-to-Revenue

DexTech Medical AB (XSAT:DEX) Debt-to-Revenue : N/A (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

DexTech Medical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. DexTech Medical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. DexTech Medical AB's annualized Revenue for the quarter that ended in Dec. 2024 was kr0.00 Mil.


DexTech Medical AB Debt-to-Revenue Historical Data

The historical data trend for DexTech Medical AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB Debt-to-Revenue Chart

DexTech Medical AB Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

DexTech Medical AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of DexTech Medical AB's Debt-to-Revenue

For the Biotechnology subindustry, DexTech Medical AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DexTech Medical AB's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DexTech Medical AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where DexTech Medical AB's Debt-to-Revenue falls into.


;
;

DexTech Medical AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

DexTech Medical AB's Debt-to-Revenue for the fiscal year that ended in Jun. 2024 is calculated as

DexTech Medical AB's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


DexTech Medical AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of DexTech Medical AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


DexTech Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.